Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BETADOSE: Reduced-dose antenatal betamethasone for prevention of neonatal complications in very preterm birth
2016-001486-90Phase 3Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Apr 2016
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in respiratory distress syndrome (RDS) and neonatal complications of very preterm birth comparing Standard-dose betamethasone with Reduced-dose betamethasone (50% dose) + placebo (2 arms). Primary endpoint: Severe respiratory distress syndrome (RDS). Started Apr 2016; status: completed.
02
Drugs
betamethasone
03
Conditions
respiratory distress syndrome (RDS)neonatal complications of very preterm birth
Beyond the preview
Go deeper on 2016-001486-90.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001486-90.